Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant antibody fragments

P J Hudson1

  • 1CRC for Diagnostic Technologies and CSIRO Molecular Science, Parkville, Victoria, Australia. peter.hudson@molsci.csiro.au

Current Opinion in Biotechnology
|August 28, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying Age Cohorts Responsible for Peste Des Petits Ruminants Virus Transmission among Sheep, Goats, and Cattle in Northern Tanzania.

Viruses·2020
Same author

Pastoral production is associated with increased peste des petits ruminants seroprevalence in northern Tanzania across sheep, goats and cattle.

Epidemiology and infection·2019
Same author

The slow dynamics of mycoplasma infections in a tortoise host reveal heterogeneity pertinent to pathogen transmission and monitoring.

Epidemiology and infection·2018
Same author

The role of shared parasites in the exclusion of wildlife hosts: Heterakis gallinarum in the ring-necked pheasant and the grey partridge.

The Journal of animal ecology·2018
Same author

Impacts of long-term precipitation manipulation on hydraulic architecture and xylem anatomy of piñon and juniper in Southwest USA.

Plant, cell & environment·2017
Same author

Parasite-mediated competition between pheasant and grey partridge: a preliminary investigation.

Oecologia·2017
Same journal

Microbial C1 assimilation pathways for chemical synthesis: from native metabolism to synthetic design.

Current opinion in biotechnology·2026
Same journal

Medicinal plants fermentation: current knowledge and perspectives.

Current opinion in biotechnology·2026
Same journal

Fermented foods: lessons learned from metagenomics.

Current opinion in biotechnology·2026
Same journal

Microfluidic platforms for the transient transfection of mammalian cells: recent developments and challenges.

Current opinion in biotechnology·2026
Same journal

Harvesting insights from recent advances in yeast genomics for predictable and precision wine fermentation.

Current opinion in biotechnology·2026
Same journal

Minimal enzyme cascades for the aromatic-to-aromatic upgrading of lignin monomers.

Current opinion in biotechnology·2026
See all related articles

Engineered antibodies are increasingly vital in medicine, with applications in cancer therapy, transplantation, and gene therapy. Advances in design and selection are enabling new therapeutic and diagnostic uses for these recombinant proteins.

Area of Science:

  • Biotechnology and Immunology
  • Protein Engineering
  • Therapeutic Antibody Development

Background:

  • Recombinant antibodies and fragments constitute over 30% of biological proteins in clinical trials.
  • Recent FDA approval highlights the therapeutic potential of engineered antibodies, particularly in oncology.
  • Existing applications include immune response enhancement for cancer and suppression of immune rejection in transplantation.

Purpose of the Study:

  • To review advances in the design, selection, and production of engineered antibodies.
  • To highlight innovative applications of recombinant antibodies and their fragments in medicine and biotechnology.
  • To discuss the expanding role of engineered antibodies in clinical trials and therapeutic strategies.

Main Methods:

Related Experiment Videos

  • Review of recent developments in antibody engineering methodologies.
  • Analysis of innovative selection techniques for isolating specific antibody functionalities.
  • Examination of diverse applications involving the conjugation of antibody fragments to various payloads.

    • Main Results:

    • Engineered antibodies are a significant component of clinical pipelines, with growing therapeutic success.
    • Novel selection methods have yielded catalytic and high-affinity viral-specific antibodies.
    • Recombinant antibody fragments are being fused with radioisotopes, drugs, toxins, enzymes, and biosensors for diverse applications.

    Conclusions:

    • Engineered antibodies represent a rapidly advancing field with broad clinical and biotechnological implications.
    • Continued innovation in antibody design and selection promises to unlock new therapeutic and diagnostic capabilities.
    • The versatility of recombinant antibody fragments supports their integration into multifaceted biomedical applications.